Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Minocin (Minocycline) for Injection in Healthy Adults

NCT ID: NCT02802631

Last Updated: 2023-12-15

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 69 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-20
• Study Completion Date: 2018-02-08

Brief Summary

This was a Phase 1, randomized, double-blind, placebo-controlled, single and multiple ascending dose study of the safety, tolerability, and pharmacokinetics of Minocin (minocycline) for injection in healthy adult participants.

Detailed Description

The purpose of this study was to collect safety, tolerability, and pharmacokinetic (PK) data on ascending dose regimens of Minocin (minocycline) for Injection. The safety, tolerability, and PK data was to support the compound as a potential clinical candidate in Europe and allow recommendations of dose levels to be used in future Phase 2/3 studies.

Conditions

Normal Healthy Volunteers

Keywords

Bacterial infections

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Minocin (minocycline) for Injection

Minocin (minocycline) for Injection was supplied as a sterile lyophilized powder in single-use 10-milliliter (mL) glass vials. Each vial contained 108 milligrams (mg) of minocycline hydrochloride equivalent to 100 mg of minocycline. Each cohort received one of the following dosages of Minocin (minocycline) for Injection: 100 mg, 200 mg, 300 mg, 400 mg, 500 mg, or 600 mg. Within each cohort, participants received a single dose on Day 1, followed by 7 days of multiple doses (Days 4 to 10, given every 12 hours), followed by a single dose on Day 11.

Group Type: EXPERIMENTAL

Minocin (minocycline) for Injection

Intervention Type: DRUG

Intravenous formulation of minocycline, a derivative of tetracycline

0.9% Sodium Chloride Injection USP

Placebo was in the form of the same 100-mL bags of normal saline (0.9% Sodium Chloride Injection United States Pharmacopeia \[USP\]). Dosing was on the same schedule as participants randomized to Minocin (minocycline) for Injection.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Placebo - Normal Saline

Interventions

Minocin (minocycline) for Injection

Intravenous formulation of minocycline, a derivative of tetracycline

Intervention Type: DRUG

Placebo

Placebo - Normal Saline

Intervention Type: OTHER

Other Intervention Names

Minocin; Minocycline

Eligibility Criteria

Inclusion Criteria

1. A signed informed consent form, the ability to understand the study conduct and tasks that were required for study participation, and a willingness to cooperate with all tasks, tests, and examinations as required by the protocol, whether in the research unit or after discharge, for the duration of the study

2. Male or female between 18 and 50 years of age inclusive

3. Participant had a body mass index ≥18 kilograms/square meter (kg/m^2) and ≤30 kg/m^2.

4. Participant was non-smoker or smokes up to 5 cigarettes per day (or equivalent).

5. Participant was in good health based on medical history and physical examination findings and had no clinically meaningful safety laboratory abnormalities (hematology, blood chemistry, and urinalysis) or 12-lead electrocardiogram results, as assessed by the Principal Investigator.

6. Vital signs (blood pressure, pulse, respiratory rate and temperature) measured at screening/baseline must have been within the following ranges: systolic blood pressure ≥90 to ≤150 millimeters of mercury (mm Hg), diastolic blood pressure ≥45 to ≤90 mm Hg; heart rate ≥45 to ≤90 beats per minute (taken after resting in a supine position for at least 5 minutes).

7. Expectation that intravenous access would be sufficient to allow for ease of study drug infusion, and for all protocol-required blood sampling to take place

8. Participant committed to remaining admitted in the research unit for the course of the study.

9. Female participant was surgically sterile, postmenopausal: period of amenorrhea for at least 2 years, or if of childbearing potential, agreed to abstinence or to use at least 2 acceptable methods of birth control (for example prescription oral contraceptives, contraceptive injections, contraceptive patch, intrauterine device, barrier methods) or male partner sterilization alone, between the first dose (Day 1) and for 90 days after the completion of the study.

Exclusion Criteria

1. Had any condition, including findings in the medical history or in pre-study assessments that constituted a risk or a contraindication for the participation in the study or completing the study

2. Positive breath test for alcohol and/or positive urine test for drugs of abuse at Screening and Day -1 Visits

3. Had a history or presence of alcohol/drug abuse within 2 years. Alcohol abuse was defined as regularly consuming >3 units/day (21 units per week for men), >2 units/day (14 units/week) for women. A unit was defined as a can of 4% beer (330 mL), approximately 190 mL of 6-7% beer (malt liquor), a glass of 40% spirits (30 mL), a glass of wine (100 mL).

4. Participant showed positive hepatitis B surface antigen, hepatitis C virus antibodies, or human immunodeficiency virus I/II antibodies and antigen tests.

5. Participant had active or ongoing candida infection.

6. Blood or plasma donation within past 2 months

7. Females who were pregnant or nursing or who had a positive pregnancy test result at the Screening Visit or Day -1 prior to dosing

8. Males who were unwilling to practice abstinence or use an acceptable method of birth control during the entire study period and for 90 days after the completion of the study (that is condom with spermicide, where locally available)

9. Presence of known raised intracranial pressure

10. Use of retinoids (for example, isotretinoin)

11. History of significant hypersensitivity or allergic reaction to any of the tetracycline class of antibiotics or the components of those antibiotics

12. Receipt of any investigational medication or investigational device during the last 30 days prior to randomization

13. Treatment with any prescription, vitamins or over-the-counter drugs, within 2 weeks or five half-lives, whichever was longer, or herbal nutritional supplements within 2 weeks of screening, with the exception of acetaminophen/paracetamol for minor headache. Participants were not allowed to receive medications for the duration of the study (except the abovementioned acetaminophen/paracetamol). Birth control or other hormone replacement were also permitted as long as it had been taken at a stable dose for at least 3 months before the Screening Visit and remained stable for the duration of the study.

14. A corrected QT interval by Fridericia >480 milliseconds

15. Calculated creatinine clearance less than 50 mL/minute (Cockcroft-Gault method) at screening or check-in (Day -1)

16. Unable or unwilling, in the judgment of the Investigator, to comply with the protocol

17. An employee of the Investigator, the study center, the sponsor or The Medicines Company with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, or a family member of the employee or the Investigator

18. Prior enrollment in any minocycline study including prior cohorts in this trial

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Universitätsklinikum Köln

OTHER

Sponsor Role: collaborator

Innovative Medicines Initiative

OTHER

Sponsor Role: collaborator

Rempex (a wholly owned subsidiary of Melinta Therapeutics, Inc.)

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dr. Naguib Muhsen, MD

Role: PRINCIPAL_INVESTIGATOR

QPS Holdings LLC

Locations

QPS

Groningen, AG, Netherlands

Countries

France; Netherlands

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

701 (IMI WP8A ID #)

Identifier Type: OTHER

Identifier Source: secondary_id

MDCO-MIN-16-02

Identifier Type: -

Identifier Source: org_study_id